← Human Trials & Peer-Reviewed Studies
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend
Plain-language guide to PMID 36588166 (2023): placebo-controlled randomized controlled trial study of Abaloparatide, osteoporosis and bone density.
Key Facts
- PMID
- 36588166
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Cosman F et al. (5 authors)
- DOI
- 10.1002/jbmr.4764
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Abaloparatide in the context of osteoporosis and bone density.
Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > -2.5.
Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD.
Who Took Part
PubMed tags the participants as women only.
Women with osteoporosis randomized to abaloparatide or placebo for 18 months (ACTIVE), followed by alendronate for 24 months (ACTIVExtend), with evaluable TBS, were included in this post hoc analysis (N = 911).
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.
The comparison arm used a placebo, so changes seen with Abaloparatide could be set against what happens without it.
The timeline in the abstract includes 18 months.
What Was Measured
Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > -2.5.
Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD.
The subject headings attached to it are Alendronate, Cancellous Bone, Osteoporotic Fractures, Spinal Fractures, Osteoporosis, Bone Density and Bone Density Conservation Agents.
Author keywords: ANABOLICS, ANALYSIS/QUANTITATION OF BONE, CLINICAL TRIALS and DXA.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Abaloparatide in people with osteoporosis and bone density over 18 months.
The publication is from 2023 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Abaloparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.